Skip to main content

Table 2 Adjusted OR for the CKD according to genotype, dominant model and allele of MnSOD Val16Ala genotype

From: The relationship between MnSOD Val16Ala gene polymorphism and the level of serum total antioxidant capacity with the risk of chronic kidney disease in type 2 diabetic patients: a nested case-control study in the Tehran lipid glucose study

Polymorphism Genotype CKD N (%) Non-CKD N (%) OR (95% CI) P Value
MnSOD Val16Ala (rs4880) Genotype
Val/Val 85 (30.4%) 57 (20.4%) 1 (ref.)  
Ala/Val 158 (56.4%) 161 (57.5%) 0.65 (0.44–0.98) 0.041
Ala/Ala 19 (6.8%) 42 (15%) 0.30 (0.16–0.57) 0.001
Dominant Genotype Model
Val/Val 177 (63.2%) 203 (72.5%) 1 (ref.) 0.006
Ala/Ala + Ala/Val 85 (30.4%) 57 (20.4%) 0.55 (0.36–0.84)
Allele
Val 328 (62.6%) 275 (52.88%) 1 (ref.) 0.004
Ala 196 (37.4%) 245 (47.12%) 0.53 (0.35–0.82)
  1. ORs (odds ratios and 95% confidence intervals) were calculated using multivariate logistic regression analysis adjusted for BMI, energy intake, total Cholesterol, LDL-Cholesterol, triglyceride, Systolic and Diastolic blood pressure, smoking status and medication; CKD chronic kidney disease. CKD was defined as estimated glomerular filtration rate < 60 ml/min/1.73 m2. eGFR estimated glomerular filtration rate, MnSOD Manganese superoxide dismutase